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LysosomeThe formation of intracellular aggregates containing α-synuclein (α-Syn) is one of the key steps in the progres-
sion of Parkinson's disease and dementia with Lewy bodies. Recently, it was reported that pathological α-Syn
ﬁbrils can undergo cell-to-cell transmission and form Lewy body-like aggregates. However, little is known
about how they form α-Syn aggregates from ﬁbril seeds. Here, we developed an assay to study the process of
aggregate formation using ﬂuorescent protein-tagged α-Syn-expressing cells and examined the aggregate
forming activity of exogenous α-Syn ﬁbrils. α-Syn ﬁbril-induced formation of intracellular aggregates was
suppressed by a cathepsin B speciﬁc inhibitor, but not by a cathepsin D inhibitor. α-Syn ﬁbrils pretreated with
cathepsin B in vitro enhanced seeding activity in cells. Knockdown of cathepsin B also reduced ﬁbril-induced
aggregate formation. Moreover, using LAMP-1 immunocytochemistry and live-cell imaging, we observed that
these aggregates initially occurred in the lysosome. They then rapidly grew larger andmoved outside the bound-
ary of the lysosome within one day. These results suggest that the lysosomal protease cathepsin B is involved in
triggering intracellular aggregate formation by α-Syn ﬁbrils.
© 2015 Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Alpha-synuclein (α-Syn) is a major component of Lewy bodies
(LBs), which are the intracellular pathological inclusions seen in
synucleinopathies such as Parkinson's disease (PD), and dementia
with Lewy bodies (DLB). α-Syn oligomers/ﬁbrils are considered to
underlie the disturbances of a number of intracellular processes includ-
ing mitochondrial functions (Protter et al., 2012) and protein degrada-
tion processes (Xilouri et al., 2013), which may ﬁnally induce
neuronal death. Studies using the brains of patients with PD have
indicated that LB and Lewy neurite pathologies occur ﬁrst in a few
speciﬁc regions of the lower brain stem and olfactory bulb, and then
spread into other regions of the brain as the disease progresses (Braak
et al., 2004). Furthermore, recent studies have demonstrated the ability
of α-Syn ﬁbrils to transfer between cells, both in cultured cells and in
mice (Desplats et al., 2009; Emmanouilidou et al., 2010; Alvarez-Erviti
et al., 2011). Thus, it is now considered that the propagation of LB
pathology in the brains of PD patients is in part due to the transmission
of pathogenic polymerized forms of α-Syn. Knowledge about each step
of this α-Syn transfer is being accumulated; for example, it was founda).
ect.com).
icle under the CC BY-NC-SA license (that pathological α-Syn oligomers or ﬁbrils can be internalized via
endocytic pathways (Lee et al., 2005; Sung et al., 2001). Incorporated
α-Synﬁbrils are preferentially processed for degradation by the autoph-
agy–lysosomal pathway (ALP) (Watanabe et al., 2012). Some α-Syn
aggregates can induce the rupture of lysosomes following their endocy-
tosis in neuronal cell lines (Freeman et al., 2013); on the other hand, α-
Syn may also be secreted via exosome-mediated release (Danzer et al.,
2012; Marques and Outeiro, 2012). However, the process by which α-
Syn undergoes nucleation-dependent accumulation into LB-like
aggregates in cells has not been fully elucidated. There have been a
considerable number of in vitro and in vivo studies of oligomerization/ﬁ-
brillation from the unfolded α-Syn monomer (Giasson et al., 1999;
Conway et al., 1998; Hashimoto et al., 1998), and of aggregate formation
after the introduction of α-Syn seeds (Luk et al., 2012a,b; Sacino et al.,
2013). We also recently suggested that intracellular aggregate forma-
tion induced by exogenousα-Syn ﬁbrils is dependent on the expression
level of endogenous α-Syn in hippocampal neurons (Taguchi et al.,
2014). However, the initiation step in aggregation from the ﬁbril
template has not been fully investigated.
In the present study, using an α-Syn-enhanced cyan ﬂuorescent
protein (ECFP)-expressing cell line, we established a system to evaluate
the seeding activity of in vitro-prepared α-Syn ﬁbrils into aggregates.
Using this system, we unexpectedly found that cathepsin B, which is
one of the proteolytic enzymes responsible for degrading proteins inhttp://creativecommons.org/licenses/by-nc-sa/3.0/).
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and that intracellularα-Syn aggregates begin to appear in the lysosome.
Materials and methods
Chemicals and antibodies
Three α-Syn antibodies, anti-α-Syn polyclonal antibody (C20)
(Santa Cruz Biotechnology, Inc. CA), anti-α-Syn monoclonal antibody
(syn-1) (BD Bio Sciences, New Jersey) and anti-phosphorylated α-Syn
(pSyn) antibody (Ser129) (Wako Pure Chemical Industries Ltd, Osaka,
Japan) were used in this study. Anti-GFP and anti-LC3 antibodies were
purchased from Medical & Biological Laboratories Co., Ltd. (Nagoya,
Japan). Anti-LAMP-2 monoclonal antibody was purchased from BD Bio
Sciences (New Jersey). Anti-cathepsin B antibody was purchased from
Sigma-Aldrich (St Louis, MO). Sertralinewas purchased from Tocris Bio-
science (Bristol, UK). Protease inhibitors, pepstatin A, CA-74Me, and E-
64d were purchased from Peptide Institute Inc. (Osaka, Japan), and
LysoTracker Red DND-99 was purchased from Thermo Fisher Scientiﬁc
Life Technologies Invitrogen (Massachusetts).
Cell culture
Cells were grown in DMEM medium supplemented with 10%
fetal bovine serum. Human α-Syn cDNA was cloned into pECFP-N1
(TAKARA BIO INC., Otsu, Japan) and the resulting expression vector
was transfected into HEK293F cells with Lipofectamine 2000 (Thermo
Fisher Scientiﬁc, Invitrogen). After selection with 400 μg/ml G418, a
clonal-derived HEK293F/Syn-ECFP cell linewas used in the intracellular
aggregate-forming assay.
Preparation of recombinant α-Syn and its aggregates
Humanα-Syn cDNAwas ampliﬁed by PCR (forward primer, 5′-ATCA
TATGGATGTATTCATGAAAGG-3′; reverse primer, 5′-ACAAGCTTGGCTTC
AGGCTCATAGTC-3′) and the resultant fragmentwas digestedwith NdeI
and HindIII, and then cloned into NdeI-HindIII sites of the pET43.1a
E. coli expression vector (Merck Millipore, MA). The PrimeSTAR Muta-
genesis Basal Kit (Takara Bio Inc.) was used to make a α-Syn S129A
point mutation according to the manufacturer's instructions using
the synthetic primers S129A_FW 5′-CCTGCTGAGGAAGGGTATCAAGAC
TA-3′ and Mut-Re1 5′-CATTTCATAAGCCTCATTGTCAGGATCC-3′. Re-
combinant α-Syn was expressed in E. coli strain BL21 codonPlus (DE3)
(Agilent Technologies, Santa Clara, CA) with 1 mM IPTG induction and
recovered by osmotic shock into buffer consisting of 25 mM Tris–HCl/
1 mM EDTA, pH 8.0. The recovered periplasmic fraction was boiled for
10min and insoluble debriswas removed by centrifugation. The cleared
supernatant containing recombinant α-Syn was charged on a Hitrap Q
column (GE Healthcare, UK) and eluted with a 0–1MNaCl linear gradi-
ent. Finally, the protein was desalted with disposable PD-10 Desalting
Columns with PBS and stored at−20 °C.
Fibril forms of α-Syn were prepared in accordance with a previous
report (Volpicelli-Daley et al., 2011). Brieﬂy,ﬁbrils ofα-Synwere gener-
ated by incubating puriﬁed α-Syn in PBS at a ﬁnal concentration of
2 mg/ml with constant agitation (500 rpm) at 37 °C for 168 h. Then,
ﬁbrils were recovered by ultracentrifugation (110,000 ×g, 20 min),
resuspended in PBS with brief sonication and stored at −20 °C. In
vitro protein aggregation was monitored using the ProteoStat protein
aggregation assay kit (Enzo Life Sciences, Plymouth Meeting, PA) and
a CytoFluor2300 system (Thermo Fisher Scientiﬁc, Applied Biosystems)
equipped with excitation 530 nm and emission 590 nm ﬁlters.
Intracellular aggregate forming assay
For the assay, 1 μg or less ofα-Synmonomer/oligomer/ﬁbrils in 25 μl
of DMEM medium (resuspended with brief sonication) and 1 μl ofDMRIE-C transfection reagents (Thermo Fisher Scientiﬁc, Invitrogen)
in 25 μl DMEM were combined and incubated for 20 min at room
temperature. The complex solution was then mixed with 50 μl of
trypsin-isolated HEK293F/Syn-ECFP cell suspension (1 × 105/50 μl) in
96-well plates. After incubation for 30 min at 37 °C, 100 μl of DMEM
medium containing 20% FBS was added and incubated for a further
16–48 h in a 5% CO2 incubator. The formation of aggregates in the
transfected cells was monitored using a ﬂuorescence microscope. For
the quantitation of intracellular aggregation, the culture medium
was discarded by decantation and the cells were overlaid with PBS
containing 0.1% Triton X-100 and 0.1 μg/ml DAPI (4′,6-diamidino-
2-phenylindole) followed by gentle rotation for 30 min in the dark.
The Triton X-100-insoluble punctate ﬂuorescence images were
photographed using a IX71 ﬂuorescence microscope (Olympus, Tokyo,
Japan) and analyzed using the image-processing program “Image J”
with “Analyze Particle” menu (Schneider et al., 2012).
For inhibitor assay, cells were treated for 30 min in DMEMmedium
with respective compound before addition ofα-Syn ﬁbrils. After 30min
incubation with ﬁbrils, 100 μl of DMEM medium containing respective
inhibitor and 20% FBS was added.
The effect of in vitro digestion of α-Syn ﬁbrils with cathepsin B
In vitro-prepared α-Syn ﬁbrils (500 μg/ml) were digested with
proteinase K (concentration range 48–3125 ng/ml in PBS) or cathepsin
B (concentration range 16–1000 ng/ml in 25 mM MES pH 5.0/1 mM
EDTA/1 mM DTT) at 37 °C for 60 min followed by heat inactivation of
enzymes at 95 °C for 5 min. Digested ﬁbrils were analyzed by assess-
ment of intracellular aggregate formation and western blotting.
Knockdown of cathepsin expression by siRNA
SiRNA sequences targeting human CTSB were synthesized by Bex
Co., Ltd (Tokyo, Japan). The siRNA sequences were: sense, 5′-GAGUUA
UGUUUACCGAGGAtt-3′; anti-sense, 5′-UCCUCGGUAAACAUAACUCtt-
3′ (Parreno et al., 2008).
The HEK293F/Syn-ECFP cells were transfected with siRNAs at a ﬁnal
concentration of 25 nM using RNAiMAX (Thermo Fisher Scientiﬁc,
Invitrogen) according to the manufacturer's instructions. Forty-eight
hours after transfection, cellswere collected in trypsin for the intracellu-
lar aggregate forming assay. The efﬁciency of cathepsin gene knock-
down was evaluated by assessing the enzyme activities of the cell
lysate with the ﬂuorogenic substrates Z-Arg-Arg-MCA and MOCAc-
Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2, (Peptide
Institute Inc.) according to the recommended procedure.
Knockdown of autophagy pathways by siRNAs
SiRNA sequences against human ATG5 and LAMP-2 genes have been
described previously (Watanabe and Tanaka, 2011; Gonzalez-Polo et al.,
2005). ATG5 gene knockdown was evaluated by suppression of LC3-II
accumulation by 1 μM rapamycin (Wako Pure Chemical Industries
Ltd) treatment for 6 h in the growthmedium. LAMP-2 gene knockdown
was by reduction of LAMP-2 protein content in the cell lysate by
western blottingwith anti-LAMP-2 antibody.We also conﬁrmed reduc-
tion of both genes by quantitative PCR with appropriate primer sets:
ATG5; 5′-TTGACGTTGGTAACTGACAAAGT-3′/5′-TGTGATGTTCCAAGGA
AGAGC-3′ (Watanabe et al., 2012); and LAMP-2; 5′-TGGCAATGATAC
TTGTCTGCTG-3′/5′-ACGGAGCCATTAACCAAATACAT-3′.
Immunocytochemistry
Cells were ﬁxed with 2% paraformaldehyde (PFA) in cultured medi-
um for 10min at room temperature. The ﬁxed cells were permeabilized
with 0.1% Triton X-100 in PBS for 10 min, and blocked with 5% normal
goat serum (NGS) in PBS for 30 min. Next, cells were incubated with
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washed with PBS, and further treated with secondary antibody.
For double-staining, this staining procedure was repeated for each
antigen and the primary antibodies were detected by Alexa488- and
Alexa594-conjugated antibodies (Thermo Fisher Scientiﬁc, Molecular
Probes). These cells were washed with PBS followed by DAPI staining.
They were then washedwithmilliQ water (MerckMillipore), and ﬁnal-
ly mounted with FluorSave (MerckMillipore). Images were acquired as
a Z stack (20–30 z-sections, 0.3–0.5 μm apart, 1024 × 1024) through
Plan-Apochromat 40×/1.30 or 63×/1.40 Oil DIC objective lenses (Carl
Zeiss, Oberkochen, Germany) with an inverted laser-scanning confocal
microscope, LSM510 (Carl Zeiss) (Watanabe and Tanaka, 2011).
Time-lapse imaging of aggregate formation
For time-lapse monitoring of the intracellular aggregation formation
process, HEK293F/Syn-EGFP cells were transfected with α-Syn ﬁbrils in
collagen-coated 16-well chamber slides (Thermo Fisher Scientiﬁc, Nunc,
#178599) and visualized under aﬂuorescentmicroscope IX71 (Olympus)
equippedwith a Stage Top incubator (TOKAIHIT, Shizuoka Japan). Images
were captured using a 40× objective at 15-minute intervals.
Statistics
Data are expressed as the means ± standard errors. p values were
calculated by one-way ANOVA followed by Tukey's post-hoc test.
Results
Establishment of an assay system to measure intracellular aggregate
formation by α-Syn ﬁbrils in cultured cells
To investigate the process underlying formation of intracellular LB-
like aggregates, we established a HEK293F cell line stably expressingFig. 1. Quantitative seeding activity assay for α-Syn aggregates. (A) Representative images of
ﬁbrils into the Syn-ECFP-expressing cells (HEK293F/Syn-ECFP cells), cells started to form aggr
ECFP with Triton X-100, only detergent-resistant α-Syn aggregates were retained in the cytop
and to allow correction for cell number (right panels). (B) Aggregate formation was examine
using “Image J” and presented as graphs (*p b 0.05, **p b 0.01 from the no ﬁbril control).α-Syn fused to ECFP (HEK293F/Syn-ECFP cells). Under normal growth
conditions, ECFP ﬂuorescence was present uniformly in the cells and
no aggregationwas observed at all.When in vitro-preparedα-Synﬁbrils
(Luk et al., 2009) were introduced into the cells, a large condensed
ﬂuorescent signal began to appear 4 h after introduction. It was possible
to observe in real-time the formation of aggregates in these cells. How-
ever, to quantify the accumulated ﬂuorescent signals accurately was
impossible because of ﬂuorescence owing to non-participating α-Syn-
ECFP in the cytoplasm. To overcome this limitation of quantiﬁcation,
we employed a simple washout process using 0.1% Triton X-100 (Sacino
et al., 2013). Permeabilization of cell membranes allowed soluble α-
Syn-ECFP to diffuse out of cells, but the detergent-resistant aggregates
were retained (Fig. 1A). Varying amounts of in vitro-prepared α-Syn
ﬁbrils produced detergent-resistant ﬂuorescent signals in HEK293F/Syn-
ECFP cells, and a good correlation was obtained between the amounts
of input α-Syn ﬁbrils (Fig. 1B) and the number of particles (Fig. 1C), the
total area (Fig. 1D), and the size of the signals (Fig. 1E). The insoluble α-
Syn-ECFP aggregates were analyzed by conventional western blotting
after separation of Triton X-100-insoluble protein by centrifugation (Sup-
plementary Fig. S1). The levels of insolubleα-Syn-ECFP aggregates on the
PVDFmembranes appeared to increase in a dose-dependentmannerwith
the amount of introduced α-Syn ﬁbrils. However, it was considered that
accurate quantiﬁcation of aggregates on western blotting membranes
was difﬁcult because of the increase in the amounts of ladders and
smeared bands derived fromα-Syn-ECFPwith a structure that is not sep-
arable on SDS-PAGE (Supplementary Fig. S1).
Monomeric α-Syn was polymerized by stirring in vitro to obtain
ﬁbril samples (Volpicelli-Daley et al., 2011), so that the process of aggre-
gation could be monitored indirectly by an assay with ﬂuorescent dye
binding (Supplementary Fig. S2A) or sedimentation of the aggregates
by ultracentrifugation (Supplementary Fig. S2B). When α-Syn mono-
mer or in vitro samples have received b48 h of agitation were intro-
duced into HEK293F/Syn-ECFP cells, no intracellular aggregate
formation was observed (Supplementary Fig. S2C). However, whenthe intracellular aggregate quantiﬁcation process are shown. After introduction of α-Syn
egates in the cytoplasm within a few hours (lower left panel). After washout of free Syn-
lasm (lower middle panel). DAPI staining was performed to conﬁrm the presence of cells
d using varying amounts of α-Syn ﬁbrils. (C–E) Then, ﬂuorescent signals were analyzed
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ﬁbrils (Supplementary Fig. S2B),were introduced into cells, intracellular
α-Syn-ECFP aggregates were observed as bright ﬂuorescent signals and
the number and size of aggregates increased with agitation time. We
decided to use ﬁbrils created by 168 h of stirring as seeds. Measuring
the total area of aggregates is considered as an appropriate means of
representing the seeding activity of ﬁbril-containing samples. The intro-
duction α-Syn ﬁbrils and the ﬁbril-induced formation of intracellular
aggregates for 24 h were not toxic to the HEK293F/Syn-ECFP cells
based on a lactate dehydrogenase (LDH) assay, excluding a possible
inﬂuence of cell toxicity from this assay (Supplementary Fig. S2D).
Inhibition of lysosomal function suppresses α-Syn aggregate formation
To investigate the pathways mediating intracellular aggregate
formation by α-Syn, we examined several inhibitors of the proteasome
and ALP because disturbances of these degradation pathways are
involved in protein aggregation (Ebrahimi-Fakhari et al., 2012). As
shown in Figs. 2A and B, lactacystin, a proteasome inhibitor, had no
effect on aggregate formation, but baﬁlomycin A1 and NH4Cl, which
neutralize lysosomal pH, strongly suppressed it in HEK293F/Syn-ECFP
cells. This result suggested that lysosomal functions were involved in
aggregate formation. Then, the effects of inhibitors of lysosomal
enzymes on the degree of aggregate formation were examined. E-64d,
an inhibitor of cysteine proteases, and CA-074Me, a cathepsin B-
speciﬁc inhibitor, signiﬁcantly blocked aggregate formation. Cathepsin
B is a cysteine protease found abundantly in lysosomes. In contrast,
pepstatin A, an inhibitor of aspartic proteases represented by cathepsin
D, had no effect. In general, inhibition of the proteolytic process leads to
accumulation of proteins destined for degradation. Itwas a surprise that
the opposite result to what we anticipated was obtained from the
cathepsin B inhibitor experiment. We introduced α-Syn ﬁbrils and
performed LDH assays using cathepsin B or cathepsin D inhibitor up to
72 h later. Following ﬁbril introduction, LDH levels signiﬁcantly
increased at 48 h and 72 h, but not 24 h. However, toxicity was not
different among groups treated with DMSO, Ca74Me, or pepstatin A
(Supplementary Fig. S2E), and may be due to the long-term effects of
ﬁbril introduction.Fig. 2. Effect of inhibitors on intracellular aggregate formation. Various inhibitors that affect intr
(A) Representativeﬂuorescence images of TritonX-100-resistant inclusions are shown in inhibi
cells are attached for the conﬁrmation of the existence of the cells. Scale bar = 20 μm. (B) The
gregate formation in theDMSO control sample. The inhibitors usedwere 0.1% DMSO (0.1%) as a
64d (5 μM) and pepstatin A (5 μM). **p b 0.01 vs. the DMSO control. (C) The effect of endocytoWe also investigated the role of endocytosis in aggregate formation
using sertraline, an endocytosis inhibitor, to suppress dynamic GTPase
activity (Takahashi et al., 2010). With sertraline, we observed marked
inhibition ofα-Syn aggregate formation (Fig. 2C), suggesting that exog-
enous α-Syn ﬁbrils enter the cell and reach lysosomes via endocytosis.
In vitro digestion of α-Syn ﬁbrils by cathepsin B enhances seeding activity
As shown in Fig. 2, cathepsin B may promote aggregate formation
activity. Therefore, next, we examined whether the seeding activity
was inﬂuenced by the extent of digestion of α-Syn ﬁbrils by cathepsin
B, with proteinase K digestion used as a control. Proteinase K preferen-
tially digests proteins after hydrophobic amino acids; therefore,
proteinase K induced almost complete digestion of α-Syn ﬁbrils and
intracellular aggregates were not formed (Figs. 3A and B, left). In con-
trast, cathepsin B digestion enhanced intracellular aggregate formation
activity, which increased together with an increase in cathepsin B
concentration (Figs. 3A and B, right). Cathepsin B preferentially cleaves
-Arg-Arg-|-Xaa bonds in small molecule substrates (UniProt: P07858).
However, human α-Syn does not have such sequences for cleavage.
Thus, the levels of partially cathepsin B-digested ﬁbrils and slightly
truncated α-Syn were present at increased levels on SDS-PAGE gels
(Fig. 3B, right, arrows a and b). Moreover the band indicated by arrow
‘b’ and shorter truncated bands were not recognized by the C20
antibody, which was raised against the C-terminal region of human α-
Syn (Fig. 3D). This increase in aggregate-forming activity might be
attributed to C-terminally truncated ﬁbril seeds formed owing to the
dipeptidyl carboxypeptidase activity of cathepsin B with broad
substrate speciﬁcity (Koga et al., 1991).
Knockdown of the cathepsin B gene leads to decreased α-Syn aggregate
formation
To examine the effect of cathepsin B gene (CTSB) suppression on α-
Syn aggregate formation, the CTSB gene was knocked down by siRNA.
As shown in Fig. 4A, the enzymatic activity of cathepsin B in the cell
lysate was suppressed to 45% by the CTSB siRNA. Using cells with
reduced cathepsin B activity, intracellular α-Syn aggregate formationacellular pH gradient and proteolysiswere added during intracellular aggregate formation.
tor-treatedHEK293F/Syn-ECFP cells afterα-Synﬁbril introduction. Images of DAPI-stained
effects of the reagents on aggregate formation are represented as the % of the level of ag-
control, NH4Cl (20mM), baﬁlomycin A1 (10 nM), lactacystin (5 μM), CA-074Me (5 μM), E-
sis inhibitor sertralin (10 μM) is represented as (B).
Fig. 3. In vitro cathepsin B digestion enhanced aggregate-forming activity. In vitro-preparedα-Synﬁbrils were digestedwith proteinase K or cathepsin B at various enzyme concentrations.
(A) The intracellular aggregate-forming activitywasmeasured on the basis of protease-digestedﬁbrils. The concentration of the enzyme increases from left to right (PK0andCB0 represent
noenzyme controls, PK1 to PK7 represent proteinase K concentrations from48 ng/ml to 3125ng/ml doubling each time, and CB1 to CB7 represent cathepsinB enzyme concentrations from
16 ng/ml to 1000 ng/ml doubling each time). *p b 0.05, **p b 0.01 vs. no enzyme control. (B) The degrees of cleavage by the enzymes were analyzed by western blotting using antiα-Syn
monoclonal antibody (syn-1). Bands with distinguishable intensity changes associated with cathepsin B concentration were labeled with arrows “a” and “b”. The molecular weights of
monomeric α-Syn, and bands a and b on SDS-PAGE, correspond to 17.6, 16.4, and 14.9 kDa, respectively. (C) Proﬁle plots for lanes PK0, PK7, CB0 and CB7 in (B) are shown.
(D) Western blotting of the CB7 sample using syn-1 and C20 anti-α-Syn antibodies.
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in CTSB knocked down cells (Fig. 4B). Because cathepsin B was reported
to be required for the activation of cathepsin D in lysosomes (Laurent-
Matha et al., 2006), there was a possibility that the reduction of
aggregate formation by CTSB knockdown was a result of the reduction
in cathepsin D activity. However, as shown in Fig. 4A, the cathepsin D
activity was not affected by CTSB knockdown, excluding the involve-
ment of cathepsin D. Considering together the results of these experi-
ments using speciﬁc inhibitors and siRNA, cathepsin B is considered to
be responsible for the enhancement of α-Syn aggregate-forming
activity.
Autophagy pathways are involved in α-Syn aggregate formation
In addition to endosome trafﬁcking, autophagy pathways are known
to be involved in intracellular protein transport to lysosomes (Saftig and
Klumperman, 2009). Thus, we examined the contribution of autophagy
by knockdown experiments using siRNA-ATG5 or siRNA-LAMP-2.
Inhibition of macroautophagy by siRNA-ATG5 treatment led to a
decrease in intracellular aggregate formation to 51% of control siRNA
levels (Figs. 5A–C). Inhibition of chaperone-mediated autophagy
(CMA) by siRNA-LAMP-2 also decreased aggregate formation to 61%of control levels, which was comparable to reductions in LAMP-2 gene
and protein expression (Figs. 5D–F). These results indicate that both
macroautophagy and CMA are involved in aggregate formation after
incorporation of α-Syn ﬁbrils.
Intracellular α-Syn aggregate formation begins in the lysosome
Because cathepsin B was involved in the aggregate formation by
exogenous α-Syn ﬁbrils in the above experiments, we next examined
visually the location and growth of intracellular aggregates using the
anti-pSyn antibody, which reportedly recognizes phosphorylated α-
Syn at position serine 129 in synucleinopathy lesions (Fujiwara et al.,
2002). As shown in Fig. 6A, exogenous α-Syn ﬁbrils were surrounded
by the lysosomal membrane marker LAMP-1 at 4 h after introduction
of ﬁbrils into the cells. It was considered that the seeding activity of
the introduced ﬁbrils was acquired in the lysosomes. Then, we
examined the expression of newly formed aggregates after mutant α-
Syn S129A ﬁbril introduction. This time the anti-pSyn exclusively
recognizes endogenous α-Syn. Intracellular aggregates appeared with
small and weak phosphorylation signals within a few hours, and then
gradually increased in number and size over time (Figs. 6B–D). Regard-
ing the changes in size, the size-distributions of aggregates on confocal
Fig. 4.Knockdown of the cathepsin B gene led to decreased aggregate-forming activity. (A)HEK293F/Syn-ECFP cells were transfectedwith an siRNA against the cathepsin B gene (CTSB) or
a control siRNA for 2 days and cathepsin B and cathepsin D activities in the cell lysate were measured using ﬂuorogenic substrates. The enzymatic activity of cathepsin B was decreased to
45% of the control level by the speciﬁc siRNA. The enzymatic activity of cathepsin Dwas not inﬂuenced by treatmentwith CTSB siRNA. (B) The intracellular seeding activity for aggregates
formationwas alsomeasured afterα-Syn ﬁbril introduction. Similarly, seeding activity was also reduced to 56% of the control level after treatmentwith CTSB siRNA. Data are presented as
the mean ± standard errors (**p b 0.01 from the control siRNA).
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Fig. S3). Three hours after ﬁbril introduction, approximately 70% of the
intracellular aggregates were classiﬁed into the smallest fraction. As
incubation time increased, the proportion of the smallest size fraction
decreased, and the amount of larger aggregates increased (Supplemen-
tary Fig. S3). It was concluded that the intracellular aggregates begin as
small aggregates, and grow larger within a day in this system.Fig. 5. Involvement of autophagy pathways in aggregate formation. Autophagy pathway compo
α-Syn aggregates and calculated total area of intracellular aggregates in siRNA treated cells w
(B) Introduction of siATG5 suppressed rapamycine induced LC3-II accumulation analyzed byW
titative PCR. (D) LAMP-2 gene knockdown reduced ﬁbril-induced aggregate formation to 61% o
creased to 60%, as determined by western blotting. (F) Knockdown of LAMP-2 gene expressionNext, we examined the growth and localization of intracellular
pSyn-positive aggregates with special reference to the coexistence
with LAMP-1 (Fig. 6E). Intracellular aggregates showed one of three
different forms: (a) they were completely included in the LAMP-1
signals; (b) they were partially surrounded by LAMP-1 signal; or
(c) they existed independently from LAMP-1 signal. For example,
compared with the aggregates shown in panel (a) of Fig. 6E, largernent genes were knocked downusing speciﬁc siRNAs. (A) Images of Triton X-100 resistant
ere shown. ATG5 gene knockdown reduced aggregate formation to 51% of control levels.
estern blottingwith anti LC3 antibody. (C) ATG5 gene knockdownwas conﬁrmed by quan-
f control levels. (E) Intracellular content of LAMP-2 protein in siRNA treated cells was de-
was determined by quantitative PCR. **p b 0.01 vs. siControl.
Fig. 6. Lysosomes as a location for intracellular aggregate formation. The location and development of newly generated aggregates were analyzed. (A) At 4 h after human α-Syn ﬁbril
introduction into HEK 293 cells, which do not expressα-Syn, the intracellular location of exogenousα-Syn ﬁbril was examined by double immunocytochemistry using antibodies against
anti pSyn (red) and the lysosomal marker LAMP-1 (green). White dashed lines indicated the contours of the cells. White box areas were enlarged and merged images with x-z and y-z
images were arranged. (B) Representative ﬂuorescence images of the formation and the growth of intracellular aggregates along the time course after ﬁbril introduction. Intracellular
aggregates in HEK293F/Syn (without ECFP tag) cells, formation of which was initiated by in vitro-prepared S129A mutant ﬁbrils, were stained with anti-pSyn antibody. (C), (D) The
quantiﬁed time course-change of the number (C) and size (D) of intracellular aggregates on microscopic images of the same samples in (B). “Two hundred pixels” in (D) are equivalent
to the area of a circlewith a diameter of 5 μm in (B). (E) Confocal microscopic images of the three typical relationships of the intracellular aggregates to LAMP-1 staining are shown.White
dashed lines in the panels indicate the contours of the cells. (F) Percentage of intracellular aggregates existing with LAMP-1 ((a) and (b) in panel (E) combined) are summarized. The data
in (C), (D) and (F) are presented as the means ± standard errors (*p b 0.05, **p b 0.01 from the 3-h samples in (C) and (D), and from the 2-h sample in (F), respectively).
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somal structure (panel (b)). Aggregates that coexisted with LAMP-1
(Figs. 6E-a and b) were counted at each time point examined after ﬁbril
introduction (Fig. 6F). The percentage of coexistence of pSyn aggregates
and LAMP-1 showed a peak at 6 h, and then began decreasing. At 21 h,
almost no aggregates coexisting with LAMP-1 were seen (Fig. 6F).
Live-cell imaging of growing α-Syn aggregates in cells
We also performed time-lapse imaging of intracellular aggregates
forming in living HEK293F/Syn-EGFP cells (Supplementary Movies
S1–3). In α-Syn-EGFP expressing cells, there were always dark regions
lacking EGFP ﬂuorescence in the cytoplasm (Figs. 7A, B). After 5 h of
α-Syn ﬁbril introduction, small aggregates that appeared brighter than
the cytoplasm began to appear in the dark compartments. These gradu-
ally grew larger and ﬁlled the dark places with aggregates (Figs. 7A a–c,
SupplementaryMovies S1–3). The cells in which aggregations grew to a
large size tended to rapidly consume endogenous Syn-EGFP molecules
for aggregate formation resulting in a reduction in cytoplasmic ﬂuores-
cence (Figs. 7Ac). Next, we stained these dark compartments with
LysoTracker or LAMP-1 antibody (at 6 h afterα-Syn ﬁbril introduction).
While cytoplasmic dark compartments in HEK293F/Syn-EGFP cells
were not stained with LysoTracker (white arrow heads in Fig. 7B
upper panels), most of them were LAMP-1-positive (white arrows in
Fig. 7B lower panels). The LysoTracker probes are used to detect acidic
organelles in living cells and normal lysosomes are usually positive for
both LysoTracker and LAMP-1 (Supplementary Fig. S4). These LAMP-
1-positive/LysoTracker-negative dark compartments are considered to
be impaired lysosomes. Based on these observations, it is strongly
suggested that the initiation of aggregate formation takes place in the
lysosomes after α-Syn ﬁbril treatment, and the growth of aggregates
is followed by their escape from the impaired lysosomes.
Discussion
Although several groups have reported the formation of LB-like
aggregates in cells by exogenous α-Syn ﬁbrils, how they grow into
larger molecules involving endogenous α-Syn is still unknown (Luket al., 2009; Nonaka et al., 2010; Watanabe et al., 2012; Tanik et al.,
2013). To address this issue, we developed an assay system for forming
detergent-insoluble α-Syn aggregates using HEK293 cells stably
expressing α-Syn-ECFP. This system easily enabled the quantiﬁcation
of the ﬂuorescence intensity of α-Syn-containing intracellular aggre-
gates and quantiﬁcation of the number and size of aggregates. Recently
Guo et al reported that there are at least two conformational variations
of sarkosyl-insoluble α-Syn in PD brains (Guo et al., 2013). Thus, in
addition to assessing in vitro-prepared ﬁbrils, the present assay system
could be useful for examining pathological features in synucleinopathy
patients and classifying the precise type of α-Syn pathology.
We previously observed that intracellular α-Syn inclusions, forma-
tion of which was induced by exogenous α-Syn ﬁbrils, underwent
degradation via p62/SQSTM1-dependent autophagy in HEK293 cells
(Watanabe et al., 2012). Therefore, at ﬁrst, we thought that inhibition
of the degradation pathway would be involved in the formation of
aggregates, and we treated cells with inhibitors of the ALP or the ubiq-
uitin–proteasome system. Unexpectedly, treatment with baﬁlomycin
A1, which blocks vacuolar H+-ATPase (V-ATPase) and prevents fusion
between autophagosomes and mature lysosomes (Yamamoto et al.,
1998), decreased aggregate formation, while the proteasome inhibitor
lactacystin did not affect aggregate formation. Klucken et al also report-
ed this baﬁlomycin A1-induced inhibition of aggregation using α-Syn-
transfected H4 cells, whichwere prone to development ofα-Syn aggre-
gates (Klucken et al., 2012). They also showed that another V-ATPase
inhibitor, chloroquine, substantially reduced aggregation, but that 3-
methyladenine, which inhibits autophagy by blocking autophagosome
formation, did not. Moreover, NH4Cl treatment, which blocks acidiﬁca-
tion, reduced aggregate formation in this study. Recently, Buell et al.
reported that, in the presence of preformed ﬁbrils, the multiplication
of aggregates was much faster at lower pH values below 6 than at
normal physiological pH values in vitro (Buell et al., 2014). These lines
of evidence suggest that lysosomal function is important for initiating
aggregation from the seed of α-Syn ﬁbrils.
It is generally thought that lysosomal impairment causes α-Syn
accumulation (Dehay et al., 2013). In fact, concerning another abundant
lysosomal enzyme, cathepsin D, there were reports that a deﬁciency of
cathepsin D or overexpression of an inactivemutant cathepsin D caused
Fig. 7. α-Syn aggregates emerge from dysfunctional lysosomes. (A) Three representative time-lapse image sequences of intracellular α-Syn aggregate formation are shown. Time after
ﬁbril transfection into HEK293F/syn-EGFP cells is shown as h:mm above the images. White arrows indicate the positions of arising α-Syn intracellular aggregates. (B) Upper panels
show the ﬂuorescence images of living HEK293/syn-EGFP cells, whichwere stainedwith LysoTracker Red at 6 h afterα-Syn ﬁbril introduction. Lower panels show the immunocytochem-
istry ofﬁbril-transfectedHEK293/syn-EGFP cells using anti-GFP and anti-LAMP-1 antibodies. Arrowheads indicate the cytoplasmic dark compartments that exclude EGFPﬂuorescence and
LysoTracker signals, and arrows indicate those stained with LAMP-1 signals.
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Crabtree et al., 2014). In the present study, we observed that cathepsin
D inhibitor had no effect on aggregate formation. There may not have
been enough time to enhance endogenous α-Syn expression and
aggregate formation in this assay system. Thus, our present study
revealed that, among lysosomal enzymes, cathepsin B is responsible
for the activation of α-Syn seeds. This may be attributed to the fact
that α-Syn does not have a typical consensus recognition sequence for
cathepsin B. α-Syn ﬁbrils pre-treated with cathepsin B in vitro were
not completely digested and slightly truncated forms appeared after
digestion in a high enzyme concentration on western blots. This pre-treatmentwith high doses of cathepsin B causedmore aggregate forma-
tion in cells (Fig. 3). In the case of C-terminal truncated α-Syn, it
enhances the aggregation of the more abundant full-length α-Syn
in vitro and in vivo (Murray et al., 2003; Li et al., 2005; Ulusoy et al.,
2010). In fact, LB extracts contain up to 15% C-terminal truncated α-
Syn (Baba et al., 1998). Transgenic mice with truncated human α-Syn
(1-120), driven by the tyrosine hydroxylase promoter, show pathologi-
cal inclusions in the substantia nigra and olfactory bulb (Tofaris et al.,
2006). Furthermore, Games et al. recently reported that reducing C-
terminal truncated α-Syn by passive immunization in mThy1-α-Syn
transgenic mice, attenuated neurodegeneration (Games et al., 2014).
252 A. Tsujimura et al. / Neurobiology of Disease 73 (2015) 244–253These reports suggest that C-terminal truncated α-Syn plays an impor-
tant role in pathogenesis of synucleinopathies. In this study, cathepsin
B-induced partially cleaved and/or conformationally changed α-Syn
ﬁbrils are supposed to gain nucleation activity and induce formation
of intracellular aggregates ofα-Syn. The precise mechanism underlying
the modulation of α-Syn ﬁbrils by cathepsin B will be clariﬁed in a
future study.
Endocytosis is involved in cellular uptake of exogenousα-Syn ﬁbrils.
Our ﬁndings suggest that after endocytosis, macroautophagy plays a
part in transport of α-Syn ﬁbrils to lysosomes. We previously showed
that exogenous ﬁbrils colocalized with LC3 1 h after introduction into
HEK 293 cells. As there is no endogenous α-Syn, exogenous ﬁbrils
underwent further degradation through the ALP (Watanabe et al.,
2012). In the present study, suppression of α-Syn aggregate formation
by siRNA-ATG5may be owing to inhibition ofα-Syn ﬁbril trafﬁcking be-
fore the ﬁbrils attain seeding activity in lysosomes, as ATG5 is involved
in elongation of isolated membranes in autophagosome formation
(Kuma et al., 2004). On the other hand, CMA reportedly contributes to
α-Syn monomer transfer to lysosomes and subsequent degradation
(Cuervo et al., 2004; Xilouri et al., 2009). SiRNA-LAMP-2 treatment
may inhibit transport of endogenous α-Syn monomers into lysosomes
and prevent initiation of intracellular aggregate formation. Further in-
vestigation will clarify intracellular transport of α-Syn ﬁbrils after
transfection.
We observed that aggregate formation begins in the lysosome. From
4 h after ﬁbril introduction, small aggregates including endogenous
phosphorylated α-Syn appeared. At ﬁrst, they were surrounded by a
lysosomal marker, LAMP-1 (Figs. 6E-a). Endogenous soluble α-Syn is
recruited to exogenous α-Syn ﬁbrils and is converted into insoluble,
hyperphosphorylated, and ubiquitinated pathological species in
cultured cells (Luk et al., 2009). Enhanced or overexpressed neuronal
α-Syn is degraded in the lysosome via CMA in vivo (Mak et al., 2010).
Thus, the lysosome seems to provide a place of aggregation from ﬁbril
seeds in the early period after introduction. Our present data showed
that more than 90% of α-Syn aggregates were not colocalized with
LAMP-1 at 21 h after ﬁbril introduction (Fig. 6F). Freeman et al recently
reported that in vitro-prepared α-Syn aggregates could induce rupture
of the lysosome following their endocytosis after 24 h in neuronal cell
lines (Freeman et al., 2013). Using an HEK293 model of LB–like aggre-
gates, Tanik et al reported that the amounts of giant lysosomes
increased 24 h after introduction of preformed ﬁbrils and, at that time,
α-Syn aggregates were not colocalized with LAMP-1 (Tanik et al.,
2013). Collectively, based on these results and our own, we propose a
model in which α-Syn seeds are initially activated in the lysosome by
cathepsin B, rapidly grow larger and incorporate endogenous α-Syn,
and escape from the lysosome 24 h after introduction.
Recently it was reported that LB-like aggregates are spread in the
brain by inoculating α-Syn ﬁbrils (Luk et al., 2012a,b; Masuda-Suzukake
et al., 2013). Precise knowledge about the process underlying intracellu-
lar α-Syn aggregation after seeding with ﬁbrils will contribute to new
therapeutic strategies for PD and DLB in the future.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.10.011.
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